Teams
Epiliv Team
Ajoutez votre titre ici
The “Epigenetics, microenvironment and liver diseases” team aims to better understand and target chronic liver diseases.
It is organized around 3 main axes:
Axis 1. Chronic hepatitis B and D: viral persistence, pathogenicity and cure strategies
Axis 2. Inflammation, metabolism and epigenetics: towards an integrative biology of hepatic steatosis
Axis 3. Critical liver care: targeting perioperative lesions in liver surgery and transplantation
Context
Liver disease is a major health threat worldwide, including in Europe. Chronic liver disease affects more than 1.5 billion people worldwide: chronic infection with hepatitis viruses is a major public health burden, with 58 million people infected with HCV and 300 million with HBV. In addition, 10% of the world’s population is at risk of alcoholic liver disease (ALD) due to excessive alcohol consumption. Due to the continuing rise in obesity and metabolic syndrome, 25% of the population suffer from hepatic steatosis or metabolic steatohepatitis (MASLD).
In total, chronic liver disease (CLD) is responsible for over 2 million deaths a year, linked to complications of liver cirrhosis (end-stage liver disease – ESLD – and hepatocellular carcinoma – HCC). HCC ranks 5th among the most frequent cancers and 3rd in cancer deaths. Liver transplantation (LT) remains an essential, life-saving intervention for patients with end-stage liver disease or HCC. However, access to transplantation and increasing the number of available grafts remain major challenges.
Overall, Chronic Liver Diseases (CLD) have a major impact on public health and economic costs, with individual health costs multiplied by 4. Despite advances in diagnosis, the availability of curative treatment for hepatitis C, long-term suppressive therapies for chronic hepatitis B, new systemic treatments for advanced HCC, and better therapeutic options for many causes of HCC, their overall burden continues to grow. They remain largely undiagnosed or untreated, particularly in migrant populations.
The structuring of the intrahepatic microenvironment, via the interaction between host factors (genetic, epigenetic, immunological, metabolic) and exogenous/environmental factors (viruses, toxins, lifestyle), and its evolution, influence both disease progression and response to treatment.
In line with the strategic vision of the research unit “Pathobiology and Therapy of Liver Diseases” and building upon the broad expertise of its members across basic, translational, and clinical research in liver diseases the EpiLiv teams will develop, in close link with the IHU EVEREST, three consistent axes:
- Axis 1. Chronic hepatitis B and D: virus persistence, pathogenicity and new strategies for cure
- Axe 2. Interplay between inflammation, metabolism, and epigenetics: from liver integrative biology to an actionable blueprint of steatotic liver disease (SLD)
- Axe 3. Hepatic critical care: targeting perioperative injury in liver surgery and transplantation
Axis I. Chronic hepatitis B and D: virus persistence, pathogenicity and new strategies for cure
In the context of the broader research effort of the research unit towards the development of new anti-HBV and anti-HDV treatments, EpiLiv will aim to increase our understanding of the mechanisms of viral persistence and immune control and to identify and validate novel non-invasive biomarkers.
Objectives :
In the context of the broader research effort of PaThLiv towards the development of new anti-HBV and anti-HDV treatments, EpiLiv will aim to increase our understanding of the mechanisms of viral persistence and immune control and to identify and validate novel non-invasive biomarkers of the intrahepatic viral reservoir and immune correlates of cure, namely through the aims below:
- Specific aim 1.1 (EpiLiv) : HDV ribonucleoprotein (RNP), histone mimicry and chromatin remodelers: role in HDV replication and pathogenicity.
- Specific aim 1.2 (EpiLiv) : Virological and immunological correlates of cure in CHB patients.
- Specific aim 1.3 (HeLiP & EpiLiv) : Re-educating the liver micro-environment.
- Specific aim 1.4 (HeLiP & EpiLiv) : Novel non-invasive biomarkers of intrahepatic cccDNA pool activity.
Axis II. Interplay between inflammation, metabolism, and epigenetics: from liver integrative biology to an actionable blueprint of steatotic liver disease (SLD)
EpiLiv research Axis 2 combines functional investigations aimed at elucidating the interplay between inflammation, metabolism, epigenetics and the gut and liver microbioma with a multiomics profiling that comprises bulk and single cell transcriptomics, spatial transcriptomics, high-definition MS metabolomics and lipidomics and metabolomics/lipidomics. The feasibility of the ambitious translational research effort is guaranteed by the growing transcriptomics facility managed by EpiLiv at the current UMR location and the tight collaboration with the metabolomics / lipidomics platforms at the Institute of Analytical Sciences (S. Ayciriex). The following aims will embody these efforts.
Objectives :
- Specific aim 2.1 (EpiLiv) : Inflammatory and metabolic drivers in steatotic liver disease (SLD).
- Specific aim 2.2 (EpiLiv) : Linking metabolism and epigenetics in fatty liver disease progression to HCC.
- Specific aim 2.3 (EpiLiv) : Role of the histone methyltransferase EZH2 in the modulation of cancer-associated and metabolic pathways in hepatocellular carcinoma.
- Specific aim 2.4 (EpiLiv & HeLiP) : Clinical, immunological, and epigenetic profiling of end stage liver diseases (ESLD).
Axis III. Hepatic critical care: targeting perioperative injury in liver surgery and transplantation
In the context of the rapid increase in the burden of CLD, ESLD and HCC, liver surgery including resection and transplantation represents a major curative treatment option. However, surgical care remains challenging: in 2020 in France, 1838 patients were listed for transplantation, but only 1128 were transplanted.
Through implementation of the aims below, EpiLiv will:
i) develop new predictive models for the prioritization of patients in the waiting list for LT;
ii) investigate the pathophysiological mechanisms underlying two major post-operative liver specific injuries (e.g., ischemia-reperfusion injury and hemodynamic dysfunction);
iii) identify biomarkers to predict the severity and outcome of these injuries;
iv) evaluate treatment strategies to mitigate these injuries and improve short and long-term outcomes.
Objectives :
- Specific aim 3.1 (EpiLiv & HeLiP) : New predictive models for patients prioritization of in the waiting list for LT.
- Specific aim 3.2 (EpiLiv) : Mitigating ischemia-reperfusion injury in liver surgery and transplantation.
- Specific aim 3.3 (EpiLiv) : Mitigating hemodynamic injury in liver surgery and transplantation.
Team overview
The “Epigenetics, microenvironment and liver cancer” (EpiLiv) team aims to better understand and target chronic liver diseases.
Principal investigators: A. Blet (PUPH), Y. Chouik (PHU), J. Dumortier (PUPH), K. Mohkam (PUPH), X. Muller (CCA), M. Levrero (PUPH), J.Y. Mabrut (PUPH), P. Merle (PUPH), A. Paturel (MCU), G. Rossignol (MCU-PH), C. Trépo (PUPH emeritus), M. Zeisel (DR)
Tenured ITA: M.L. Plissonnier (IR)
Other members: 2 post-docs, 4 PhD students, 1 Master 2 student, 1 technician
Funding: ANRS, H2020 IP-cure-B (“immune profiling to guide host-directed interventions to cure HBV infections”), INCa, Ligue contre le cancer.
Collaborations: Zoulim, B. Testoni (HeLiP), A. Vaillant (Replicor Inc), P. Lampertico (UniMi Milan), H. Strick-Marchand (Institut Pasteur Paris), M. Dandri (UKE Hamburg), A. Böckman (IBCP Lyon), C. Ferrari (UniPa Parma), S.- G. Lim (NUS Singapore), R. DasGupta (A-STAR Singapore), C. Soulette (Gilead Sciences, Foster City), F. Lebossé (HeLiP), S. Ayciriex (ISA Lyon), N. Benech (CHU Lyon), D. Vocadlo (Simon Fraser University, Canada).
Projets
Publications
2025
Alfano V, Pascucci GR, Corleone G, Cocca M, De Nicola F, Floriot O, Paturel A, Di Tocco FC, de Fromentel CC, Merle P, Rivoire M, Levrero M, Guerrieri F. HBV-driven host chromatin accessibility changes affect liver metabolic pathways, iron homeostasis and promote a preneoplastic phenotype. J Exp Clin Cancer Res. 2025 May 16;44(1):146. doi: 10.1186/s13046-025-03414-7. PMID: 40380227; PMCID: PMC12082925.
Yang Y, Delcourte L, van Belleghem C, Fonte S, Gerard K, Baconnais S, Callon M, Le Cam E, Fogeron ML, Levrero M, Faivre-Moskalenko C, Böckmann A, Lecoq L. Structure and nucleic acid interactions of the SΔ60 domain of the hepatitis delta virus small antigen. Proc Natl Acad Sci U S A. 2025 May 13;122(19):e2411890122. doi: 10.1073/pnas.2411890122. Epub 2025 May 5. PMID: 40324079; PMCID: PMC12088457.
Stern C, Loustaud-Ratti V, Yurdaydin C, Brancaccio G, Jachs M, Reiberger T, Bardou-Jacquet E, Metivier S, Alric L, Colombain L, Meszaros M, Mathurin P, Yardeni D, Etzion O, Neumann-Haefelin C, Douglas M, Poulin S, Bazinet M, Metin RO, Vitale A, Gaeta GB, Schwarz M, Ben-Ali S, Bedoya JU, Testoni B, Zoulim F, Plissonnier ML, Levrero M, Paradis V, Francois S, de Freitas C, Kaysin F, Lecomte L, Morvan C, Schramko J, Bondezi K, Baril MÉ, Brichler S, Gerber A, Gordien E, Mackiewicz V, Dahari H, Svicher V, Chevaliez S, Vaillant A, Bourliere M. Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program. J Hepatol. 2025 Nov 6:S0168-8278(25)02612-1. doi: 10.1016/j.jhep.2025.10.029. Epub ahead of print. PMID: 41205755.
Kennedy PT, Allweiss L, Bertoletti A, Cornberg M, Gehring AJ, Guidotti LG, Kerth HA, Lemoine M, Levrero M, Lim SG, Tavis JE, Testoni B, Tu T; International Coalition to Eliminate HBV. Scientific and medical evidence informing expansion of hepatitis B treatment guidelines. Lancet Gastroenterol Hepatol. 2025 Oct;10(10):941-951. doi: 10.1016/S2468-1253(25)00053-6. Epub 2025 Jul 23. PMID: 40714040.
Degasperi E, Sandmann L, Wedemeyer H, Lampertico P; Delta Cure 2024 Working Group. Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report From the Third Delta Cure Meeting 2024. Liver Int. 2025 Jul;45(7):e70189. doi: 10.1111/liv.70189. PMID: 40540405.
Caussy C, Vergès B, Leleu D, Duvillard L, Subtil F, Abichou-Klich A, Hervieu V, Milot L, Ségrestin B, Bin S, Rouland A, Delaunay D, Morcel P, Hadjadj S, Primot C, Petit JM, Charrière S, Moulin P, Levrero M, Cariou B, Disse E. Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study. Diabetes Care. 2025 Jun 1;48(6):877-886. doi: 10.2337/dc24-2075. PMID: 39887699.
Degasperi E, Scholtes C, Testoni B, Renteria SU, Anolli MP, Charre C, Facchetti F, Plissonnier ML, Sambarino D, Perbellini R, Monico S, Callegaro A, García-Pras E, Lens S, Cortese MF, Forns X, Pérez-Del-Pulgar S, Heil M, Levrero M, Zoulim F, Lampertico P. Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta. J Hepatol. 2025 Jun;82(6):1004-1011. doi: 10.1016/j.jhep.2024.11.051. Epub 2024 Dec 9. PMID: 39662705.
Pais R, Chouik Y, Moga L, Lebedel L, Silvain C, Genser L, Weill D, Larrue H, Malézieux E, Jezéquel C, Robert M, Regnault H, Dumortier J, Ratziu V, Thabut D, Rudler M. Transjugular Intrahepatic Portosystemic Shunt (TIPS): A Bridge to Bariatric Surgery in Morbidly Obese Patients with Cirrhosis and Clinically Significant Portal Hypertension. Obes Surg. 2025 Feb;35(2):395-405. doi: 10.1007/s11695-024-07583-w. Epub 2024 Dec 29. PMID: 39739182.
Lesurtel M, Mohkam K, Allard MA, Adam R, Robin F, Rayar M, Boudjema K, Chebaro A, Boleslawski E, Savier E, Scatton O, Girard E, Chirica M, Dokmak S, Soubrane O, Faitot F, Bachellier P, Hervieu V, Guerre P, Atfeh J, Pantel S, Thevenon S, Maynard M, Pradat P, Mabrut JY. A French multicenter randomized controlled trial of hypothermic oxygenated perfusion in extended criteria donor liver transplantation. Am J Transplant. 2025 Oct 17:S1600-6135(25)03053-9. doi: 10.1016/j.ajt.2025.10.006. Epub ahead of print. PMID: 41110608.
Rossignol G, Muller X, Dubois R, Mohkam K, Mabrut JY. Hemodynamic graft-recipient matching in pediatric liver transplantation: Just graft with the flow. J Hepatol. 2025 Dec;83(6):e280-e282. doi: 10.1016/j.jhep.2025.07.035. Epub 2025 Aug 20. PMID: 40846183.
Li Z, Pfister M, Raptis DA, Ma Y, Yang G, Li L, Song X, Millet G, Truant S, Venezia R, Jeddou H, Le Floch B, Valverde A, Peru N, Pessaux P, Codiglione FG, Mabrut JY, Mohkam K, Cunha AS, Salloum C, Blanc PY, Roy BL, Goumard C, Scatton O, Tzedakis S, Fuks D, Chaoui I, Rammohan A, da Silva SG, Sobral MSN, Lopez-Lopez V, Centonze L, Zhu Z, Ratti F, Marino R, Rompianesi G, Dong Y, Shah J, Müller PC, Wakabayashi T, Coelho FF, Castillo-Flores S, Lee B, Viti V, Kato Y, Boggi U, Han HS, Polanco P, Goh BKP, Cheung TT, Efanov M, Panaro F, Machado M, Herman P, Wakabayashi G, Ielpo B, Müller BP, Mejia A, Starlinger P, Martinie J, Troisi RI, Aldrighetti L, Chen G, Robles-Campos R, Choi GH, Liu R, Di Benedetto F, Marques HP, Sucandy I, Rela M, D’Hondt M, Brustia R, Soubrane O, Broering DC, Clavien PA. Novel Benchmark for Robotic Liver Resection – Bridging Tradition with Innovation. Ann Surg. 2025 May 20. doi: 10.1097/SLA.0000000000006759. Epub ahead of print. PMID: 40391433.
Peloso A, Pietrasz D, Daillier E, Cylly L, Scatton O, Goumard C, Mabrut JY, Mohkam K, Lesurtel M, Dokmak S, Jeddou H, Boudjema K, Allard MA, Adam R, Sa Cunha A, Azoulay D, Cherqui D, Vibert E, Golse N. Resection and partial liver transplantation from deceased donors with delayed total hepatectomy (RAPID procedure) for hepatocellular carcinoma: a national, multicenter, non-randomized, prospective trial. BMC Cancer. 2025 May 9;25(1):848. doi: 10.1186/s12885-025-14127-7. PMID: 40346479; PMCID: PMC12063376.
Avolio AW, Spoletini G, Cillo U, Croome K, Oniscu G, Burra P, De Santibanes M, Egawa H, Gastaca M, Guo Z, Lai Q, Martins PN, Polak WG, Quintini C, Rela M, Sapisochin G, Wiederkehr J, Pravisani R, Balci D, Leipnitz I, Boin I, Braun F, Caccamo L, Camagni S, Carraro A, Cescon M, Chen Z, Ciccarelli O, De Carlis L, Feiwen D, Di Benedetto F, Ekser B, Ettorre GM, Garcia-Guix M, Ghinolfi D, Grat M, Gruttadauria S, Hammond J, Hu Z, Junrungsee S, Lesurtel M, Mabrut JY, Maluf D, Mazzaferro V, Mejia G, Monakhov A, Noonthasoot B, Nadalin S, Nguyen BM, Nghia NQ, Patel M, Perera T, Perini MV, Pulitano C, Romagnoli R, Salame E, Subhash G, Sudhindran S, Ito T, Tandoi F, Testa G, Taner T, Tisone G, Vennarecci G, Vivarelli M, Giannarelli D, Pasciuto T, Pascale MM, Agopian V; and the global IMPROVEMENT study group. Protocol for an international multicenter, prospective, observational, non-competitive, study to validate and optimise prediction models of 90-day and 1-year allograft failure after liver transplantation: The global IMPROVEMENT Study. Updates Surg. 2025 Jun;77(3):645-664. doi: 10.1007/s13304-025-02078-4. Epub 2025 Mar 27. PMID: 40146444; PMCID: PMC12226705.
Devauchelle P, Bignon A, Breteau I, Defaye M, Degravi L, Despres C, Godon A, Guérin R, Lavayssiere L, Lebas B, Maurice A, Monet C, Monsel A, Reydellet L, Roullet S, Rozier R, Guichon C, Weiss E; French Special Interest Group “Liver Anesthesiology and Intensive Care”. Perioperative Management During Liver Transplantation: A National Survey From the French Special Interest Group in “Liver Anesthesiology and Intensive Care”. Transplantation. 2025 Apr 1;109(4):671-680. doi: 10.1097/TP.0000000000005264. Epub 2025 Mar 19. PMID: 40071909
2024
Roca Suarez AA*, Plissonnier ML*, Grand X, Michelet M, Giraud G, Saez-Palma M, Dubois A, Heintz S, Diederichs A, Van Renne N, Vanwolleghem T, Daffis S, Li L, Kolhatkar N, Hsu YC, Wallin JJ, Lau AH, Fletcher SP, Rivoire M, Levrero M, Testoni B, Zoulim F. TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism. Gut. 2024 Nov 11;73(12):2012-2022. doi: 10.1136/gutjnl-2023-331396. PMID: 38697771.
Roca Suarez AA*, Plissonnier ML*, Michelet M, Dubois A, Heintz S, Saez-Palma M, Delphin M, Bordes I, Molle J, Diederichs A, Rodà M, Combe E, Mougené L, Giraud G, Grand X, Rivoire M, Levrero M, Testoni B, Zoulim F. Protocol for isolating CD163+ Kupffer cells from human liver resections. STAR Protoc. 2024 Dec 20;5(4):103359. doi: 10.1016/j.xpro.2024.103359. Epub 2024 Oct 4. PMID: 39368096; PMCID: PMC11491951.
Paturel A, Casuscelli di Tocco F, Bousquet D, Plissonnier ML, Grand X, Tak H, Berby F, Scholtès C, Testoni B, Zoulim F, Levrero Mc. A molecular standard for circulating HBV RNA detection and quantification assays in patients with chronic hepatitis B. JHEP Rep. 2024 May 25;6(10):101124. doi: 10.1016/j.jhepr.2024.101124. PMID: 39328324; PMCID: PMC11424956.
Chouik Y, Aubin A, Maynard-Muet M, Segrestin B, Milot L, Hervieu V, Zoulim F, Disse E, Levrero M, Caussy C. The grade of obesity affects the noninvasive diagnosis of advanced fibrosis in individuals with MASLD. Obesity (Silver Spring). 2024 Jun;32(6):1114-1124. doi: 10.1002/oby.24033. Epub 2024 May 3. PMID: 38699960.
Chouik Y, Di Filippo M, Radenne S, Dumortier J, Moulin P, Levrero M. Combination of heterozygous APOB gene mutation with PNPLA3 and TM6SF2 variants promotes steatotic liver disease, cirrhosis and HCC development. Liver Int. 2024 Jun;44(6):1474-1477. doi: 10.1111/liv.15837. Epub 2024 Feb 29. PMID: 38421084.
Salerno D, Peruzzi G, Giuseppe Rubens Pascucci, Levrero M, Belloni L, Pediconi N. miRNA-27a-3p is involved in the plasticity of differentiated hepatocytes. Gene. 2024 Jun 30;913:148387. doi: 10.1016/j.gene.2024.148387. Epub 2024 Mar 17. PMID: 38499211.
Testoni B, Scholtès C, Plissonnier ML, Paturel A, Berby F, Facchetti F, Villeret F, Degasperi E, Scott B, Hamilton A, Heil M, Lampertico P, Levrero M, Zoulim F. Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B. Gut. 2024 Mar 7;73(4):659-667. doi: 10.1136/gutjnl-2023-330644. PMID: 37879886; PMCID: PMC10958289.
Narmada BC, Khakpoor A, Shirgaonkar N, Narayanan S, Kim Aw PP, Singh M, Ong KH, Owino CO, Ting Ng JW, Yew HC, Binte Mohamed Nasir NS, Au VB, Sng R, Kaliaperumal N, Toe Wai Khine HH, Casuscelli di Tocco F, Masayuki O, Naikar S, Ng HX, Chia SL, Yi Seah CX, Alnawaz MH, Lee Yoon Wai C, Ling Tay AY, Singh MK, Chew V, Yu W, Connolly JE, Periyasamy G, Plissonnier ML, Levrero M, Lim SG, DasGupta R. Single cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity. J Hepatol. 2024 Feb 27:S0168-8278(24)00137-5. doi: 10.1016/j.jhep.2024.02.017. Epub ahead of print. PMID: 38423478.
Begré L, Boyd A, Salazar-Vizcaya L, Suter-Riniker F, Béguelin C, Rockstroh JK, Günthard HF, Calmy A, Cavassini M, Stöckle M, Schmid P, Bernasconi E, Levrero M, Zoulim F, Wandeler G, Rauch A; Swiss HIV Cohort Study (SHCS). Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy. HIV Med. 2024 Feb;25(2):291-298. doi: 10.1111/hiv.13561. Epub 2023 Oct 10. PMID: 37816492.
Adam R, Badrudin D, Chiche L, Bucur P, Scatton O, Granger V, Ducreux M, Cillo U, Cauchy F, Lesurtel M, Mabrut JY, Verslype C, Coubeau L, Hardwigsen J, Boleslawski E, Muscari F, Jeddou H, Pezet D, Heyd B, Lucidi V, Geboes K, Lerut J, Majno P, Grimaldi L, Boukhedouni N, Piedvache C, Gelli M, Levi F, Lewin M. Safety and feasibility of chemotherapy followed by liver transplantation for patients with definitely unresectable colorectal liver metastases: insights from the TransMet randomised clinical trial. EClinicalMedicine. 2024 Apr 27;72:102608. doi: 10.1016/j.eclinm.2024.102608. PMID: 38721015; PMCID: PMC11077272.
Godet C, Sabbagh C, Beyer-Berjot L, Ouaissi M, Zerbib P, Valérie B, Manceau G, Panis Y, Buscail E, Venara A, Khaoudy I, Gaillard M, Viennet M, Thobie A, Menahem B, Eveno C, Bonnel C, Mabrut JY, Badic B, Chautard J, Eid Y, Duchalais E, Lakkis Z, Cotte E, Laforest A, Desfourneaux-Denis V, Maggiori L, Rebibo L, Niki C, Talal A, Mege D, Bonnamy C, Germain A, Mauvais F, Tresallet C, Roudie J, Laurent A, Trilling B, Bertrand M, Massalou D, Romain B, Tranchart H, Pellegrin A, Dejardin O, Alves A; French Surgical Association∗. Risk factors for emergency surgery for diverticulitis: A retrospective multicentric French study at 41 hospitals. Surgery. 2024 Jun;175(6):1508-1517. doi: 10.1016/j.surg.2024.02.009. Epub 2024 Apr 12. PMID: 38609785.
Thibaut F, Veziant J, Warlaumont M, Gauthier V, Lefèvre J, Gronnier C, Bonnet S, Mabrut JY, Regimbeau JM, Benhaim L, Tiberio GAM, Mathonnet M, Regenet N, Chirica M, Glehen O, Mariani P, Panis Y, Genser L, Mutter D, Théreaux J, Bergeat D, Le Roy B, Brigand C, Eveno C, Guillaume P; AFC working group and FREGAT network. Prognostic impact of positive microscopic margins (R1 resection) in patients with GIST (gastrointestinal stromal tumours): Results of a multicenter European study. Eur J Surg Oncol. 2024 Jun;50(6):108310. doi: 10.1016/j.ejso.2024.108310. Epub 2024 Mar 28. PMID: 38598874.
Muller X, Rossignol G, Boulanger N, Mohkam K, Mabrut JY. In situ or ex situ split: Does it all come down to static cold storage? J Hepatol. 2024 May;80(5):e210-e211. doi: 10.1016/j.jhep.2023.08.033. Epub 2023 Sep 16. PMID: 37717599.
Parant F, Delignette MC, Charpiat B, Lacaille L, Lebosse F, Monneret G, Mohkam K, Mabrut JY, Aubrun F, Heyer L, Antonini T. Tacrolimus Monitoring in Liver Transplant Recipients, Posttransplant Cholestasis: A Comparative Between 2 Commercial Immunoassays and a Liquid Chromatography-Tandem Mass Spectrometry Method. Ther Drug Monit. 2024 Apr 19. doi: 10.1097/FTD.0000000000001201. Epub ahead of print. PMID: 38648663.
Laroche S, Lim C, Goumard C, Rayar M, Cherqui D, Chiche L, Barbier L, Salamé E, Mabrut JY, Lesurtel M, Truant S, Boleslawski E, Muscari F, Hobeika C, Chirica M, Buc E, Hardwigsen J, Herrero A, Navarro F, Faitot F, Bachellier P, Regimbeau JM, Laurent A, Fuks D, Soubrane O, Azoulay D, Vibert E, Scatton O; AFC-LLR-2018 study group. Comparing indications, complexity and outcomes of laparoscopic liver resection between centers with and without a liver transplant program: a French nationwide study. HPB (Oxford). 2024 Apr;26(4):586-593. doi: 10.1016/j.hpb.2024.01.010. Epub 2024 Jan 25. PMID: 38341287.
Rossignol G, Muller X, Couillerot J, Lebosse F, Delignette MC, Mohkam K, Mabrut JY. From large-for-size to large-for-flow: A paradigm shift in liver transplantation. Liver Transpl. 2024 Mar 1;30(3):277-287. doi: 10.1097/LVT.0000000000000150. Epub 2023 Apr 12. PMID: 37039739.
Sabbagh C, Beyer-Berjot L, Ouaissi M, Zerbib P, Bridoux V, Manceau G, Karoui M, Panis Y, Buscail E, Venara A, Khaoudy I, Gaillard M, Ortega-Deballon P, Viennet M, Thobie A, Menahem B, Eveno C, Bonnel C, Mabrut JY, Badic B, Godet C, Eid Y, Duchalais E, Lakkis Z, Cotte E, Laforest A, Defourneaux V, Maggiorri L, Rebibo L, Christou N, Talal A, Mege D, Bonnamy C, Germain A, Mauvais F, Tresallet C, Ahmed O, Regimbeau JM, Roudie J, Laurent A, Trilling B, Bertrand M, Massalou D, Romain B, Tranchart H, Giger U, Dejardin O, Pellegrin A, Alves A; French Surgical Association. Risk factors for severe morbidity and definitive stoma after elective surgery for sigmoid diverticulitis: a multicenter national cohort study. Tech Coloproctol. 2024 Feb 19;28(1):34. doi: 10.1007/s10151-023-02906-y. PMID: 38369674.
Amory B, Goumard C, Laurent A, Langella S, Cherqui D, Salame E, Barbier L, Soubrane O, Farges O, Hobeika C, Kawai T, Regimbeau JM, Faitot F, Pessaux P, Truant S, Boleslawski E, Herrero A, Mabrut JY, Chiche L, Di Martino M, Rhaiem R, Schwarz L, Resende V, Calderaro J, Augustin J, Caruso S, Sommacale D, Hofmeyr S, Ferrero A, Fuks D, Vibert E, Torzilli G, Scatton O, Brustia R; AFC-ICC-2009, AFC-LLR-2018, and PRS-2019 Study Group. Combined hepatocellular-cholangiocarcinoma compared to hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Different survival, similar recurrence: Report of a large study on repurposed databases with propensity score matching. Surgery. 2024 Feb;175(2):413-423. doi: 10.1016/j.surg.2023.09.040. Epub 2023 Nov 18. PMID: 37981553.
Rossignol G, Muller X, Brunet TA, Bidault V, Hervieu V, Clement Y, Ayciriex S, Mabrut JY, Salvador A, Mohkam K. Comprehensive bile acid pool analysis during ex-vivo liver perfusion in a porcine model of ischemia-reperfusion injury. Sci Rep. 2024 Jan 29;14(1):2384. doi: 10.1038/s41598-024-52504-7. PMID: 38286808; PMCID: PMC10824768.
Muller X, Rossignol G, Couillerot J, Breton A, Hervieu V, Lesurtel M, Mohkam K, Mabrut JY. A Single Preservation Solution for Static Cold Storage and Hypothermic Oxygenated Perfusion of Marginal Liver Grafts: A Preclinical Study. Transplantation. 2024 Jan 1;108(1):175-183. doi: 10.1097/TP.0000000000004714. Epub 2023 Dec 13. PMID: 37410580.
Gil C, Beyer-Bergeot L, Sabbagh C, Zerbib P, Bridoux V, Manceau G, Panis Y, Buscail E, Venara A, Khaoudy I, Gaillard M, Viennet M, Thobie A, Menahem B, Eveno C, Bonnel C, Mabrut JY, Badic B, Godet C, Eid Y, Duchalais E, Lakkis Z, Cotte E, Laforest A, Defourneaux V, Maggiori L, Rebibo L, Christou N, Talal A, Mege D, Bonnamy C, Germain A, Mauvais F, Tresallet C, Roudie J, Laurent A, Trilling B, Bertrand M, Massalou D, Romain B, Tranchart H, Giger U, Alves A, Ouaissi M; French Surgical Association. Impact of the first wave of COVID-19 epidemy on the surgical management of sigmoid diverticular disease in France: National French retrospective study. Int J Colorectal Dis. 2023 Dec 2;38(1):276. doi: 10.1007/s00384-023-04564-w. PMID: 38040936.
Chouik Y, Corpechot C, Francoz C, De Martin E, Guillaud O, Abergel A, Altieri M, Barbier L, Besch C, Chazouillères O, Conti F, Dharancy S, Durand F, Duvoux C, Gugenheim J, Hardwigsen J, Hilleret MN, Houssel-Debry P, Kamar N, Minello A, Neau-Cransac M, Pageaux GP, Radenne S, Roux O, Saliba F, Samuel D, Vanlemmens C, Woehl-Jaegle ML, Leroy V, Duclos-Vallée JC, Dumortier J. Autoimmune hepatitis recurrence after liver transplantation: “Les jeux sont faits”. Liver Transpl. 2024 Apr 1;30(4):395-411. doi: 10.1097/LVT.0000000000000278. Epub 2023 Oct 4. PMID: 37788303.
Erard D, Villeret F, Chouik Y, Guillaud O, Scoazec JY, Caussy C, Disse E, Boillot O, Hervieu V, Dumortier J. Dual alcohol and metabolic-related liver disease: Results from a population of liver transplant patients. Liver Int. 2024 Feb;44(2):422-432. doi: 10.1111/liv.15779. Epub 2023 Nov 27. PMID: 38010979.
Sidali S, Borie R, Sicre de Fontbrune F, El Husseini K, Rautou PE, Lainey E, Goria O, Crestani B, Cadranel J, Cottin V, Bunel V, Dumortier J, Jacquemin E, Reboux N, Hirschi S, Bourdin A, Meszaros M, Dharancy S, Hilaire S, Mallet V, Reynaud-Gaubert M, Terriou L, Gottrand F, Abou Chahla W, Khan JE, Carrier P, Saliba F, Rubbia-Brandt L, Aubert JD, Elkrief L, de Lédinghen V, Abergel A, Olivier T, Houssel P, Jouneau S, Wemeau L, Bergeron A, Leblanc T, Ollivier-Hourmand I, Nguyen Khac E, Morisse-Pradier H, Ba I, Boileau C, Roudot-Thoraval F, Vilgrain V, Bureau C, Nunes H, Naccache JM, Durand F, Francoz C, Roulot D, Valla D, Paradis V, Kannengiesser C, Plessier A. Liver disease in germline mutations of telomere-related genes: Prevalence, clinical, radiological, pathological features, outcome, and risk factors. Hepatology. 2024 Jun 1;79(6):1365-1380. doi: 10.1097/HEP.0000000000000667. Epub 2023 Nov 6. PMID: 37934624.
Lerosey L, Ksiasek E, Abrahamowicz M, Antoine C, Dharancy S, Dumortier J, Doussot A, Di Martino V, Houssel-Debry P, Conti F, Francoz C, Pageaux GP, Salame E, Faitot F, Coilly A, Hardwigsen J, Decaens T, Chermak F, Muscari F, Anty R, Duvoux C, Abergel A, Minello A, Mouillot T, Binquet C, Latournerie M. Recipient age influences survival after liver transplant: Results of the French national cohort 2007-2017. Liver Int. 2024 Jun;44(6):1396-1408. doi: 10.1111/liv.15867. Epub 2024 Mar 7. PMID: 38451069.
L’ Huillier R, Michoud C, Dumortier J, Milot L. Massive peritoneal tumoral dissemination after hepatocellular carcinoma percutaneous microwave ablation with intraperitoneal CO2 insufflation. Clin Res Hepatol Gastroenterol. 2024 May 14;48(6):102376. doi: 10.1016/j.clinre.2024.102376. Epub ahead of print. PMID: 38754761.
Dumortier J, Tanguy G, Milot L, Cayot B. Diaphragmatic liver hernia with hepatic vascular adaptation: A rare case. Clin Res Hepatol Gastroenterol. 2024 Apr 30;48(6):102362. doi: 10.1016/j.clinre.2024.102362. Epub ahead of print. PMID: 38697388.
Leideck P, Nkontchou G, Elkrief L, Erard D, d’Alteroche L, Radenne S, Billioud C, Meszaros M, Regnault D, Pageaux GP, Hilleret MN, Tripon S, Guillaud O, Ollivier-Hourmand I, Ganne-Carrié N, Dumortier J. The role and evolution of partial splenic embolization over three decades: A multicentric retrospective single cohort study of 90 patients from French nationwide experience. Clin Res Hepatol Gastroenterol. 2024 Apr 26;48(6):102355. doi: 10.1016/j.clinre.2024.102355. Epub ahead of print. PMID: 38679291.
Elkrief L, Denecheau-Girard C, Magaz M, Praktiknjo M, Colucci N, Ollivier-Hourmand I, Dumortier J, Simon Talero M, Tellez L, Artru F, Meszaros M, Verhelst X, Tabchouri N, Beires F, Andaluz I, Leo M, Diekhöner M, Dokmak S, Fundora Y, Vidal-Gonzalez J, Toso C, Plessier A, Carlos Garcia Pagan J, Rautou PE; ERN RARE-LIVER; a study of VALDIG, an EASL consortium. Abdominal surgery in patients with chronic noncirrhotic extra hepatic portal vein obstruction: A multicenter retrospective study. Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000901. Epub ahead of print. PMID: 38683626.
Ollivier-Hourmand I, Lebedel L, Bartroli Alabau B, Goria O, Bureau C, Dumortier J, Heurgué A, Silvain C, De-Ledinghen V, Rautou PE, Payancé A, García Ballester T, Alvarado-Tapias E, Hernández-Gea V, Valla D, Zekrini K, Nguyen TTN, Dao T, Garcia Pagan JC, Morello R, Plessier A. Recurrent splanchnic and extrasplanchnic thrombotic events in patients with non-cirrhotic portal vein thrombosis associated with local factors. J Hepatol. 2024 Apr 26:S0168-8278(24)00284-8. doi: 10.1016/j.jhep.2024.04.016. Epub ahead of print. PMID: 38679069.
Nguyen Van R, Houssel-Debry P, Erard D, Dumortier J, Pouvaret A, Bergez G, Danion F, Surgers L, Le Moing V, Kamar N, Lanternier F, Tattevin P. Characteristics, management, and outcome of tuberculosis after liver transplant: A case series and literature review. Infect Dis Now. 2024 Apr;54(3):104869. doi: 10.1016/j.idnow.2024.104869. Epub 2024 Feb 23. PMID: 38401760.
Dumortier J, Boillot O. Conversion from twice-daily everolimus to once-daily sirolimus in long-term stable liver transplant recipients. Transpl Immunol. 2024 Apr;83:102014. doi: 10.1016/j.trim.2024.102014. Epub 2024 Feb 21. PMID: 38395088.
Lamarque C, Segaux L, Bachellier P, Buchard B, Chermak F, Conti F, Decaens T, Dharancy S, Di Martino V, Dumortier J, Francoz-Caudron C, Gugenheim J, Hardwigsen J, Muscari F, Radenne S, Salamé E, Uguen T, Ursic-Bedoya J, Antoine C, Deshayes A, Jacquelinet C, Natella PA, Leroy V, Cherqui D, Oubaya N, Duvoux C. Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC study. J Hepatol. 2024 Mar 21:S0168-8278(24)00202-2. doi: 10.1016/j.jhep.2024.03.019. Epub ahead of print. PMID: 38521171.
Huang J, Leporq B, Hervieu V, Dumortier J, Beuf O, Ratiney H. Diffusion-Weighted MRI of the Liver in Patients With Chronic Liver Disease: A Comparative Study Between Different Fitting Approaches and Diffusion Models. J Magn Reson Imaging. 2024 Mar;59(3):894-906. doi: 10.1002/jmri.28826. Epub 2023 May 27. PMID: 37243428.
Kocheise L, Piseddu I, Vonderlin J, Tjwa ET, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Riveiro Barciela M, Gevers TJG, Terziroli Beretta-Piccoli B, Londoño MC, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter JP, Fründt TW, Lohse AW, Huber S, von Felden J, Sebode M, Schulze K. PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease. Front Immunol. 2024 Jan 10;14:1326078. doi: 10.3389/fimmu.2023.1326078. Erratum in: Front Immunol. 2024 Jan 24;15:1369747. PMID: 38268921; PMCID: PMC10805832.
Lassailly G, Ningarhari M, Dumortier J, Lafforgue C, Bouye S, Amrani ME, Lebuffe G, Villers A, Truant S, Mathurin P, Louvet A, Boillot O, Boleslawski E, Dharancy S. Good outcome of liver transplantation in patients with pre-existing renal cell carcinoma. Clin Res Hepatol Gastroenterol. 2024 Jan;48(1):102266. doi: 10.1016/j.clinre.2023.102266. Epub 2023 Dec 13. PMID: 38101698.
Corpechot C, Lemoinne S, Soret PA, Hansen B, Hirschfield G, Gulamhusein A, Montano-Loza AJ, Lytvyak E, Pares A, Olivas I, Eaton JE, Osman KT, Schramm C, Sebode M, Lohse AW, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo FP, Floreani A, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Sobenko N, Villamil AM, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer AE, Deibel A, Bruns T, Große K, Wetten A, Dyson JK, Jones D, Dumortier J, Pageaux GP, de Lédinghen V, Chazouillères O, Carrat F; Global & ERN Rare-Liver PBC Study Groups. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? Hepatology. 2024 Jan 1;79(1):39-48. doi: 10.1097/HEP.0000000000000529. Epub 2023 Jul 3. PMID: 37399238.
Ringelhan M, Schuehle S, van de Klundert M, Kotsiliti E, Plissonnier ML, Faure-Dupuy S, Riedl T, Lange S, Wisskirchen K, Thiele F, Cheng CC, Yuan D, Leone V, Schmidt R, Hünergard J, Geisler F, Unger K, Algül H, Schmid RM, Rad R, Wedemeyer H, Levrero M, Protzer U, Heikenwalder M. HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx. JHEP Rep. 2024 Jun 6;6(10):101128. doi: 10.1016/j.jhepr.2024.101128. PMID: 39290403; PMCID: PMC11406364.
Begré L, Boyd A, Plissonnier ML, Testoni B, Salazar-Vizcaya L, Suter-Riniker F, Scholtès C, Béguelin C, Rockstroh JK, Günthard HF, Calmy A, Cavassini M, Hirsch HH, Schmid P, Bernasconi E, Levrero M, Wandeler G, Zoulim F, Rauch A; Swiss HIV Cohort Study. Circulating HBV RNA and Hepatitis B Core-Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy. J Infect Dis. 2024 Oct 16;230(4):e954-e963. doi: 10.1093/infdis/jiae189. PMID: 38626170; PMCID: PMC11481342.
Lau DTY, Jackson K, Picchio CA, Kramvis A, Sonderup M, Lemoine M, Matthews G, Howell J, Coffin CS, Hellard M, Lee AU, Anderson DA, Kerth HA, Lee EE, Tavis JE, Dandri M, Revill PA, Spearman CW, Penicaud C, Levrero M, El-Sayed M; ICE-HBV POC Model in Resource Limited Settings working group. Availability of point-of-care HBV tests in resource-limited settings. Lancet Gastroenterol Hepatol. 2024 Dec;9(12):1073-1076. doi: 10.1016/S2468-1253(24)00308-X. Epub 2024 Sep 19. PMID: 39305916.
Degasperi E, Scholtes C, Testoni B, Renteria SU, Anolli MP, Charre C, Facchetti F, Plissonnier ML, Sambarino D, Perbellini R, Monico S, Callegaro A, García-Pras E, Lens S, Cortese MF, Forns X, Pérez-Del-Pulgar S, Heil M, Levrero M, Zoulim F, Lampertico P. Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta. J Hepatol. 2024 Dec 9:S0168-8278(24)02759-4. doi: 10.1016/j.jhep.2024.11.051. Epub ahead of print. PMID: 39662705.
Pacella I, Pinzon Grimaldos A, Rossi A, Tucci G, Zagaglioni M, Potenza E, Pinna V, Rotella I, Cammarata I, Cancila V, Belmonte B, Tripodo C, Pietropaolo G, Di Censo C, Sciumè G, Licursi V, Peruzzi G, Antonucci Y, Campello S, Guerrieri F, Iebba V, Prota R, Di Chiara M, Terrin G, De Peppo V, Grazi GL, Barnaba V, Piconese S. Iron capture through CD71 drives perinatal and tumor-associated Treg expansion. JCI Insight. 2024 Jul 2;9(15):e167967. doi: 10.1172/jci.insight.167967. PMID: 38954474; PMCID: PMC11383606.
Boulanger N, Muller X, Dondero F, Golse N, Goumard C, Breton A, Sepulveda A, Allard MA, Savier E, Dokmak S, Pittau G, Ciacio O, Salloum C, Perdigão F, Rousseau G, Lim C, Rossignol G, Vibert E, Sa Cunha A, Mohkam K, Azoulay D, Adam R, Scatton O, Lesurtel M, Cherqui D, Soubrane O, Mabrut JY. Right Ex-situ split grafts for adult liver transplantation – A Multicenter Benchmarking Analysis. Ann Surg. 2024 Jun 18. doi: 10.1097/SLA.0000000000006401. Epub ahead of print. PMID: 38887938.
Rossignol G, Muller X, Ruiz M, Collardeau-Frachon S, Boulanger N, Depaulis C, Antonini T, Dubois R, Mohkam K, Mabrut JY. HOPE Mitigates Ischemia-Reperfusion Injury in Ex-Situ Split Grafts: A Comparative Study With Living Donation in Pediatric Liver Transplantation. Transpl Int. 2024 Jun 7;37:12686. doi: 10.3389/ti.2024.12686. PMID: 38911062; PMCID: PMC11190067.
Lavrut PM, Guillaud O, Dumortier J, Mintz E, Brun V, Heissat S, Couchonnal Bedoya E, Lachaux A, Bost M, Hervieu V. Histological features of liver disease development in the Atp7b-/- mouse: a model of Wilson’s disease. J Clin Pathol. 2024 Dec 18;78(1):51-56. doi: 10.1136/jcp-2023-209190. PMID: 37968102; PMCID: PMC11672018.
Erard D, Steiner A, Boillot O, Thimonier E, Vallin M, Veyre F, Guillaud O, Radenne S, Dumortier J. Calcineurin-Inhibitor Discontinuation Could Reduce the Risk of De Novo Malignancies After Liver Transplantation for Alcohol-Related Liver Disease. Clin Transplant. 2024 Oct;38(11):e70014. doi: 10.1111/ctr.70014. PMID: 39552184.
Moreau A, Chérifa M, Roland E, Mc Gee K, Plaud B, Gouel-Cheron A, Blet A. Exploring the Landscape of Perioperative Immediate Hypersensitivity: A Comprehensive 6-Year Monocentric Observational Analysis on Epidemiology and Risk Factors. Int Arch Allergy Immunol. 2024 Nov 21:1-5. doi: 10.1159/000542734. Epub ahead of print. PMID: 39571554.
Legrand M, Falcone J, Cholley B, Charbonneau H, Delaporte A, Lemoine A, Garot M, Joosten A, Meistelman C, Cheron-Leroy D, Rives JP, Pastene B, Dewitte A, Sigaut S, Danguy des Deserts M, Truc C, Boisson M, Lasocki S, Cuvillon P, Schiff U, Jaber S, Le Guen M, Caillard A, Bar S, Pereira de Souza Neto E, Colas V, Dimache F, Girardot T, Jozefowicz E, Viquesnel S, Berthier F, Vicaut E, Gayat E; Stop-or-Not Trial Group. Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery: The Stop-or-Not Randomized Clinical Trial. JAMA. 2024 Sep 24;332(12):970-978. doi: 10.1001/jama.2024.17123. PMID: 39212270; PMCID: PMC11365013.
Rezaee-Zavareh MS, Yeo YH, Wang T, Guo Z, Tabrizian P, Ward SC, Barakat F, Hassanein TI, Dave S, Ajmera V, Bhoori S, Mazzaferro V, Chascsa DMH, Liu MC, Aby ES, Lake JR, Sogbe M, Sangro B, Abdelrahim M, Esmail A, Schmiderer A, Chouik Y, Rudolph M, Sohal D, Giudicelli H, Allaire M, Akce M, Guadagno J, Tow CY, Massoumi H, De Simone P, Kang E, Gartrell RD, Martinez M, Paz-Fumagalli R, Toskich BB, Tran NH, Solino GA, Poltronieri Pacheco DM, Kalman RS, Agopian VG, Mehta N, Parikh ND, Singal AG, Yang JD. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis. J Hepatol. 2025 Jan;82(1):107-119. doi: 10.1016/j.jhep.2024.06.042. Epub 2024 Jul 10. PMID: 38996924; PMCID: PMC11655254.
Members
Massimo LEVRERO
Professeur des Universités - Praticien Hospitalier (UCBL - HCL)
After several years working on the hepatitis B virus, his work today focuses on understanding the evolution of liver disease at the molecular level, and characterizing the intrahepatic metabolic and inflammatory environment at different stages of the disease.
Mirjam ZEISEL
Research Director (Inserm)
Mirjam Zeisel co-leads the EpiLiv team with Massimo Levrero.
Over the past twenty years, she has addressed unmet medical needs in the field of chronic liver diseases by investigating the molecular mechanisms of virus-host interactions to identify novel targets for preventive and therapeutic strategies against hepatitis B, C and D virus infections as well as hepatocellular carcinoma.
Her current work aims to characterize the role of epigenetic and metabolic regulators for the development of chronic liver disease and hepatocellular carcinoma, in order to identify new therapeutic targets.
Alice BLET
Professeur des Universités - Praticien Hospitalier (UCBL - HCL)
Natacha BOULANGER
PhD student
Yasmina CHOUIK
Praticien Hospitalier Universitaire (PHU)
Yasmina Chouik works as a physician in Prof. Fabien Zoulim’s Hepatology Department. She studied the alterations of circulating microRNAs and T cells in acute decompensation of cirrhosis during her PhD at the Lyon Hepatology Institute (Prof. Massimo Levrero). Currently, she is focusing on the study of systemic and intra-hepatic inflammation in Metabolic dysfunction–Associated Liver Disease, as in the characterization of intra-hepatic microbiota in alcoholic liver disease. Yasmina Chouik leads the project Profil-NASH “In-depth characterization of intrahepatic inflammation in human metabolic-associated steatohepatitis”, in collaboration with Prof. Frank Tacke and Dr Adrien Guillot at the Charité Universitätsmedizin Berlin, and the project HepMAH “Intra-Hepatic Microbiota in Alcoholic Hepatitis”.
Massimiliano COCCA
Bioinformatician
Jérôme DUMORTIER
Professeur des Universités - Praticien Hospitalier (UCBL - HCL)
Domitille ERARD
PhD student
Simone FONTE
Postdoc
Léa GERMAN
PhD student
Mattéo JALMAIN
Master 2 student
Jean-Yves MABRUT
Professeur des Universités - Praticien Hospitalier (UCBL - HCL)
Hepatology surgeon and transplant expert, he is interested in all innovations that improve graft quality, implantation in the recipient, harvesting and hepatectomy techniques, and developments in surgical robotics.
Philippe MERLE
Professeur des Universités - Praticien Hospitalier (UCBL - HCL)
Kayvan MOHKAM
Professeur des Universités - Praticien Hospitalier (UCBL - HCL)
Xavier MULLER
Chef de Clinique Assistant (UCBL - HCL)
Alexia PATUREL
Maître de Conférences (UCLy)
Marie-Laure PLISSONNIER
Ingénieure de Recherche (Inserm)
Guillaume ROSSIGNOL
Maître de Conférence des Universités - Praticien Hospitalier (UCBL - HCL)
Christian TREPO
Professeur des Universités - Praticien Hospitalier (Emeritus)